menu
    • menu
    [{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"BDTX-189","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Versant Ventures"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BDTX-189","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BDTX-189","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BDTX-189","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BDTX-189","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BDTX-189","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BDTX-189","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"BDTX-189","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ J.P. Morgan"}]

    Find Clinical Drug Pipeline Developments & Deals for BDTX-189

    Menu

    BDTX-189

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Black Diamond Therapeutics

                            U.S.A arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Black Diamond Therapeutics

                            U.S.A arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BDTX-189

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Black Diamond Therapeutics to Host Webcast Presentation of Data From Phase 1 Dose-Escalation Portion of Master...

                            Details : BDTX-189 is currently being evaluated in a Phase 1/2 clinical trial (MasterKey-01) in adult patients with advanced solid tumors expressing a range of alterations of ErbB receptors, including oncogenic MasterKey mutations.

                            Product Name : BDTX-189

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 17, 2021

                            Lead Product(s) : BDTX-189

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Black Diamond Therapeutics

                            U.S.A arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Black Diamond Therapeutics

                            U.S.A arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BDTX-189

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Black Diamond Therapeutics to Present Phase 1 BDTX-189 Data in Advanced Solid Tumors at American Society of Cl...

                            Details : BDTX-189 is an orally available, irreversible, and ATP competitive small molecule inhibitor that is designed to block the function of a family of oncogenic epidermal growth factor receptor and ErbB-2 across a range of tumor types.

                            Product Name : BDTX-189

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 28, 2021

                            Lead Product(s) : BDTX-189

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Black Diamond Therapeutics

                            U.S.A arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Black Diamond Therapeutics

                            U.S.A arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BDTX-189

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Black Diamond Therapeutics to Present Pre-Clinical Data on Lead Product Candidate BDTX-189 at the 32nd EORTC-N...

                            Details : Pre-clinical data on the Company’s lead product candidate BDTX-189 will be presented at the 32nd EORTC-NCI-AACR Virtual Symposium on Molecular Targets and Cancer Therapeutics (ENA 2020).

                            Product Name : BDTX-189

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 10, 2020

                            Lead Product(s) : BDTX-189

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Black Diamond Therapeutics

                            U.S.A arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Black Diamond Therapeutics

                            U.S.A arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BDTX-189

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Black Diamond Therapeutics Presents Pre-Clinical Data on Lead Product Candidate BDTX-189 at the 32nd EORTC-NCI...

                            Details : Pre-clinical results provide support for BDTX-189’s uniquely differentiated profile as a potent and selective inhibitor of a range of allosteric ErbB oncogenic driver mutations.

                            Product Name : BDTX-189

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 26, 2020

                            Lead Product(s) : BDTX-189

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Black Diamond Therapeutics

                            U.S.A arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Black Diamond Therapeutics

                            U.S.A arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BDTX-189

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Black Diamond Therapeutics Granted Fast Track Designation by the FDA for BDTX-189 for the Treatment of HER2 Mu...

                            Details : U.S. Food and Drug Administration (FDA) granted Fast Track designation to BDTX-189 for the treatment of adult patients with solid tumors harboring an allosteric human epidermal growth factor receptor 2 (HER2) mutation.

                            Product Name : BDTX-189

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 28, 2020

                            Lead Product(s) : BDTX-189

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Black Diamond Therapeutics

                            U.S.A arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Black Diamond Therapeutics

                            U.S.A arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BDTX-189

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Black Diamond Therapeutics Announces Accepted Abstract for Lead Product Candidate BDTX-189 at American Society...

                            Details : MasterKey-01, the Company’s first-in-human Phase 1/2 clinical trial for its lead product candidate BDTX-189, will be presented as a poster presentation at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program.

                            Product Name : BDTX-189

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 13, 2020

                            Lead Product(s) : BDTX-189

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Black Diamond Therapeutics

                            U.S.A arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Black Diamond Therapeutics

                            U.S.A arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BDTX-189

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : J.P. Morgan

                            Deal Size : $100.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Black Diamond Therapeutics readies IPO

                            Details : The company’s plans for the IPO cash include financing Phase 1/2 tests of BDTX-189 and advancing preclinical development of its glioblastoma drug.

                            Product Name : BDTX-189

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 01, 2020

                            Lead Product(s) : BDTX-189

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : J.P. Morgan

                            Deal Size : $100.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Black Diamond Therapeutics

                            U.S.A arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Black Diamond Therapeutics

                            U.S.A arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BDTX-189

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Versant Ventures

                            Deal Size : $201.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Versant Ventures Announces Successful IPO by Black Diamond Therapeutics

                            Details : Black Diamond was the first company to emerge from Ridgeline, Versant’s Discovery Engine based in the Basel Technology Park.

                            Product Name : BDTX-189

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 29, 2020

                            Lead Product(s) : BDTX-189

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Versant Ventures

                            Deal Size : $201.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth